Subsequent Events	12 Months Ended
Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 22 — Subsequent Events SEC Settlement and DOJ Investigation Update: On February 4, 2016, the Company announced that it has entered into a settlement agreement with the SEC fully resolving the SEC’s investigation into possible violations of the FCPA. Under the terms of the settlement agreement, in February 2016 the Company paid a total of $12.8 million, including disgorgement, pre-judgment interest and a penalty as final settlement that was released from its restricted escrow account funded in the fourth quarter of 2015. This payment is in line with the charges the Company previously recorded and disclosed as further described in Note 18. As part of the agreement, the Company neither admitted nor denied engagement in any wrongdoing and the Company agreed to give status reports to the SEC for the next three years on its continued remediation and implementation of anti-corruption compliance measures. The DOJ has also completed its related investigation and has declined to pursue any action. Sinopharm Agreement: Effective January 1, 2016, the Company’s new contractual arrangement with its China importer and distributor for ZADAXIN, Sinopharm, will result in the later recognition (relative to practices prevailing through December 31, 2015) of a portion of the Company’s revenue invoiced to Sinopharm related to situations where the provincial tender price is greater relative to a referenced (baseline) tender price. This is due to a mechanism in the new contractual arrangement whereby the customer is invoiced at a lower base price relative to that prevailing in the previous agreement. The lower base price (as well as estimated price compensation payable due to the distributor for situations where the provincial tender price is lower than the referenced (baseline) tender price) will be recorded as revenue after the sale is completed. The distributor will then be invoiced for the portion of the price that may result from situations where the provincial tender price is greater than the referenced (baseline) tender price at a later time, and such amount will be recognized as revenue after the amount has been agreed to with the distributor. This new arrangement may impact quarterly revenue amounts and timing, especially for the first quarter of 2016.

Note 22 — Subsequent Events

SEC Settlement and DOJ Investigation Update: On February 4, 2016, the Company announced that it has entered into a settlement agreement with the SEC fully resolving the SEC’s investigation into possible violations of the FCPA. Under the terms of the settlement agreement, in February 2016 the Company paid a total of $12.8 million, including disgorgement, pre-judgment interest and a penalty as final settlement that was released from its restricted escrow account funded in the fourth quarter of 2015. This payment is in line with the charges the Company previously recorded and disclosed as further described in Note 18. As part of the agreement, the Company neither admitted nor denied engagement in any wrongdoing and the Company agreed to give status reports to the SEC for the next three years on its continued remediation and implementation of anti-corruption compliance measures. The DOJ has also completed its related investigation and has declined to pursue any action.

Sinopharm Agreement: Effective January 1, 2016, the Company’s new contractual arrangement with its China importer and distributor for ZADAXIN, Sinopharm, will result in the later recognition (relative to practices prevailing through December 31, 2015) of a portion of the Company’s revenue invoiced to Sinopharm related to situations where the provincial tender price is greater relative to a referenced (baseline) tender price. This is due to a mechanism in the new contractual arrangement whereby the customer is invoiced at a lower base price relative to that prevailing in the previous agreement. The lower base price (as well as estimated price compensation payable due to the distributor for situations where the provincial tender price is lower than the referenced (baseline) tender price) will be recorded as revenue after the sale is completed. The distributor will then be invoiced for the portion of the price that may result from situations where the provincial tender price is greater than the referenced (baseline) tender price at a later time, and such amount will be recognized as revenue after the amount has been agreed to with the distributor. This new arrangement may impact quarterly revenue amounts and timing, especially for the first quarter of 2016.